Diagnostics Solutions Strategic Priorities slide image

Diagnostics Solutions Strategic Priorities

Recent Breakthrough Device Designations (BDDs) Leading innovation recognized by the FDA FDA BDD Infectious diseases Oncology Women's health CNS Others cobasⓇ EBV: EBV in transplant patients cobasⓇ BKV: BKV in transplant patients FACT CDx (liquid biopsy assay): 70 oncogenes + MSI + bTMB ElecsysⓇ GALAD score: Diagnosis of early stage hepatocellular carcinoma ElecsysⓇ GDF-15: GDF-15 ElecsysⓇ sFlt-1/PIGF: rule- out of Preeclampsia within 1 week ElecsysⓇ B-Amyloid and ElecsysⓇ p-Tau in Cerebro Spinal Fluid assays: PET concordance and progression in Alzheimer's Disease in cachectic patients with solid tumors¹ CoaguCheck® Direct-X: Patients on Factor Xa EBV: Epstein-Barr virus; BKV: BK virus; FDA: Food & Drug Administration; CDx: Companion Diagnostics; CNS: Central nervous system; 1 Treated with Pfizer Inc.'s investigational drug PF-06946860 Roche 35
View entire presentation